Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)

Inclusion Criteria: * Men and women age of 18 years old and older. * HCV chronic Infection, genotype 1 or 2 or 3 or 4 or 5 or 6 * Naive * Bi-therapy failure, Tri-therapy 1st generation Telaprévir and Boceprevir, Sofosbuvir - pegIFN - RBV failure * Evaluation of fibrosis by non-invasive methods (Fibroscan, Fib 4, APRI) performed during the pre-inclusion period (of at least one month) or A Liver biopsy puncture of at least 24 months before the inclusion visit. * Fibrosis according to Metavir score: F0, F1, F2, F3, F4. * Compensated Cirrhosis Child-Pugh A or * Decompensated Cirrhosis (This point is applicable for patients who have cirrhosis) Exclusion Criteria: * Patient under amiodarone * Hepatocellular carcinoma HCC * Haemodialysis * Creatinine Clearance \< 30ml/min * Breastfeeding * Impossibility of using effective masculine or feminine contraception during the study and 6 months after treatment cessation. * Medications triggering conduction disturbances with long QT, 30 days prior to inclusion * QT prolongation \> 450 ms * Personal or familial history of torsade de pointes * Allergies to nucleosi(ti)des analogues. * Advanced cardiopulmonary pathology * Malignant neoplasia * The intake of anticonvulsants: Carbamazepine, eslicarbazepine, fosphenytoin, phenytoin, oxcarbazepine, pentobarbital, phenobarbital, primidone or the antimycobacterial agents: Rifabutin, rifampin